Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

Motley Fool10-13

Currently, Eli Lilly and Novo Nordisk dominate the diabetes and obesity care markets. BioAge Lab's weight loss candidate, aims to help patients lose weight without losing muscle mass. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475856303?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-10-13 02:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475856303","market":"fut","top_or_hot":-1,"title":"Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock","media":"Motley Fool","content":"<div>\n<p>Currently, Eli Lilly and Novo Nordisk dominate the diabetes and obesity care markets.\n\n\n\n\n\n\n\nBioAge Lab's weight loss candidate, aims to help patients lose weight without losing muscle mass.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInterested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-13 02:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Currently, Eli Lilly and Novo Nordisk dominate the diabetes and obesity care markets.\n\n\n\n\n\n\n\nBioAge Lab's weight loss candidate, aims to help patients lose weight without losing muscle mass.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1069344957.HKD","symbol_name":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","start_time":0,"source_url":"https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/","article_id":"2475856303","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475856303","pubTimestamp":1728757860,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4532":"文艺复兴科技持仓","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4585":"ETF&股票定投概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LLY":"礼来","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4581":"高盛持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BIOA":"BioAge Labs Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IPO":"Renaissance IPO ETF"},"translate_title":"对诺和诺德和礼来之外的减肥股感兴趣？您可能想看看这只新的IPO股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"IPO":1,"BIOA":0.9,"LLY":0.7},"content_text":"Currently, Eli Lilly and Novo Nordisk dominate the diabetes and obesity care markets.\n\n\n\n\n\n\n\nBioAge Lab's weight loss candidate, aims to help patients lose weight without losing muscle mass.\n\n\n\n\n\n\n\nBioAge just completed its IPO to continue funding clinical trials, but competition will be stiff.\n\nOne of the hottest areas of the pharmaceutical world right now revolves around blockbuster medications used to treat diabetes and chronic weight management.Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, and Zepbound are raking in billions for their developers, Novo Nordisk and Eli Lilly. With GLP-1 medications looking poised to become a new megatrend in healthcare, investors are looking for the next big opportunity outside of Novo and Lilly.Well, a little-known biopharmaceutical company called BioAge Labs (BIOA 5.65%) is looking to bring a new spin to the weight loss space, and it just completed its initial public offering (IPO).Is now a once-in-a-lifetime opportunity to get in early on the next big thing in weight loss? Let's look at several factors below and determine if BioAge Labs stock is a good opportunity right now.Taking a look at the financial pictureBioAge Labs raised $238.3 million in its IPO. Moreover, the company's S-1 Filing shows that operating expenses were $28.1 million through the first six months of 2024 -- implying an annual run rate of approximately $56 million. To keep the math simple, these figures imply that BioAge Labs has over four years of liquidity to fund its operational needs.Of course, the financial trajectory of the company will likely not be this linear. Now that BioAge Labs is public, I suspect the company will begin investing aggressively in more clinical development for its medications as well as hiring more people. Nevertheless, the company has a solid amount of cash on hand and looks well positioned to start disrupting its industry incumbents.Image source: Getty Images.Why is BioAge Labs different?A couple of months ago I wrote a piece analyzing several other pharmaceutical companies looking to make inroads in the weight loss space. With names such as Pfizer, Roche, and Amgen are vying for a seat at the table, what exactly is BioAge Labs doing that is so unique and does the company really have a shot at encroaching on Lilly and Novo?One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk as it significantly impacts energy levels, mobility, bone strength, and more.BioAge's weight loss candidate, azelaprag, aims to help patients lose weight while also retaining appropriate muscle mass. Should you buy BioAge Labs stock right now?While I see the need and key differentiator of Azelaprag compared to existing weight loss medications on the market, there are a few important ideas to explore.First, BioAge Labs is not the first company looking to solve issues pertaining to muscle mass reductions. Abbott Laboratories' protein shake, Protality, is meant to be taken as a complement to GLP-1 medications so that patients can retain muscle mass while also losing weight.Furthermore, pemvidutide from Altimmune is another candidate being tested in obesity patients looking to lose weight while preserving appropriate muscle mass.Outside of competition, my second point of concern with BioAge Labs is that it's an IPO stock. Broadly speaking, IPO stocks carry outsized volatility as investors buy more into the hype around a hot new company.Lastly, BioAge Labs is still a clinical-stage company. While the company has some exciting clinical trials in its pipeline, it will likely be years before any of its medications receive full approval from the Food and Drug Administration (FDA).Until then, BioAge Labs is more of a high-risk, high-reward opportunity that requires a lot of comfort with unknowns and speculation. In my eyes, investors are better off continuing to ride the growth waves of established players such as Lilly and Novo.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475856303"}